Eike C. Buss

2.3k total citations · 1 hit paper
31 papers, 1.2k citations indexed

About

Eike C. Buss is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Eike C. Buss has authored 31 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Eike C. Buss's work include Hematopoietic Stem Cell Transplantation (12 papers), Acute Myeloid Leukemia Research (9 papers) and RNA Interference and Gene Delivery (7 papers). Eike C. Buss is often cited by papers focused on Hematopoietic Stem Cell Transplantation (12 papers), Acute Myeloid Leukemia Research (9 papers) and RNA Interference and Gene Delivery (7 papers). Eike C. Buss collaborates with scholars based in Germany, United States and China. Eike C. Buss's co-authors include Anthony D. Ho, Christoph Lutz, Andreas Trumpp, Simon Raffel, Wolfgang Huber, Sandra Blaszkiewicz, Daniel Nowak, Simon Haas, Bianca P. Hennig and Wolf-Karsten Hofmann and has published in prestigious journals such as Blood, Nature Cell Biology and Cancer.

In The Last Decade

Eike C. Buss

30 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human haematopoietic stem cell lineage commitment is a continuous process

2017 539 citations Lars Velten, Simon Haas et al. Nature Cell Biology profile →

Peers

Countries citing papers authored by Eike C. Buss

Since Specialization

Citations

This map shows the geographic impact of Eike C. Buss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eike C. Buss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eike C. Buss more than expected).

Fields of papers citing papers by Eike C. Buss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eike C. Buss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eike C. Buss. The network helps show where Eike C. Buss may publish in the future.

Co-authorship network of co-authors of Eike C. Buss

This figure shows the co-authorship network connecting the top 25 collaborators of Eike C. Buss. A scholar is included among the top collaborators of Eike C. Buss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eike C. Buss. Eike C. Buss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy‐resistant preleukemic clones 2021 ·International Journal of Cancer ·(unknown), (unknown), Simon Raffel, Paul Theodor Pyl, Eike C. Buss, Wenwen Wang, Volker Eckstein, Anna Jauch, Andreas Trumpp, Wolfgang Huber, Anthony D. Ho, Christoph Lutz	6
2	Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Katharina Kriegsmann, (unknown), Manfred Hensel, Eike C. Buss, Mark Kriegsmann, Martin Cremer, Anthony D. Ho, Gerlinde Egerer, Patrick Wuchter, Mathias Witzens‐Harig	4
3	Long-Term Follow-up of Patients with Mantle Cell Lymphoma Treated with Venetoclax Monotherapy 2018 ·Blood ·Matthew S. Davids, Andrew W. Roberts, William G. Wierda, Kathryn Humphrey, (unknown), (unknown), Eike C. Buss, (unknown), John F. Seymour	1
4	Human haematopoietic stem cell lineage commitment is a continuous process breakdown → 2017 ·Nature Cell Biology ·Lars Velten, Simon Haas, Simon Raffel, Sandra Blaszkiewicz, Saiful Islam, Bianca P. Hennig, Christoph Hirche, Christoph Lutz, Eike C. Buss, Daniel Nowak, Tobias Boch, Wolf-Karsten Hofmann, Anthony D. Ho, Wolfgang Huber, Andreas Trumpp, Marieke Essers, Lars M. Steinmetz	539
5	Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients 2016 ·Leukemia & lymphoma ·Wenwen Wang, (unknown), Eike C. Buss, Anna Jauch, Volker Eckstein, Patrick Wuchter, Anthony D. Ho, Christoph Lutz	1
6	Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma 2014 ·Transfusion ·(unknown), Michael Schmitt, Patrick Wuchter, Eike C. Buss, Mathias Witzens‐Harig, Kai Neben, Michael Hundemer, Jens Hillengaß, (unknown), Hartmut Goldschmidt, (unknown), Anthony D. Ho, Anita Schmitt	33
7	BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL) 2014 ·Blood ·Nicola Goekbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Violaine Havelange, Eike C. Buss, Christoph Faul, Monika Brüggemann, Arnold Ganser, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou	43
8	Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography 2014 ·Blood ·Nicola Gökbuget, Andrea Wolf, Matthias Stelljes, Andreas Hüttmann, Eike C. Buss, Andreas Viardot, (unknown), Maike de Wit, Norbert Frickhofen, Maxim Kebenko, Mustafa Kondakci, Doris Kraemer, Stefan Schwartz, Hubert Serve, Karsten Spiekermann, Reingard Stuhlmann, Albrecht Reichle, Dieter Hoelzer	18
9	Identification and Separation of Normal Hematopoietic Stem Cells and Leukemia Stem Cells from Patients with Acute Myeloid Leukemia 2013 ·Methods in molecular biology ·Van T. Hoang, (unknown), (unknown), Abraham Zepeda‐Moreno, Dan Ran, Eike C. Buss, Patrick Wuchter, Volker Eckstein, Anthony D. Ho	10
10	Identifying leukemia stem cells – Is it feasible and does it matter? 2012 ·Cancer Letters ·Christoph Lutz, Van T. Hoang, Eike C. Buss, Anthony D. Ho	20
11	Leukemia stem cells 2011 ·International Journal of Cancer ·Eike C. Buss, Anthony D. Ho	52
12	Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis 2007 ·Cancer ·Stefan Früehauf, Julian Topaly, Eike C. Buss, Thomas Fischer, Oliver G. Ottmann, Bertold Emmerich, Martin C. Müller, Peter Schuld, Leopold Balleisen, Rüdiger Hehlmann, Anthony D. Ho, Andreas Hochhaus	43
13	Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma 2007 ·Bone Marrow Transplantation ·Stefan Früehauf, (unknown), Johannes Huesing, Marlon R. Veldwijk, Eike C. Buss, Julian Topaly, Thomas Seeger, Lior Zeller, Thomas Moehler, Anthony D. Ho, Hartmut Goldschmidt	36
14	Retroviral MDR1 gene transfer into marrow-engrafting human peripheral blood progenitor cells results in preferential transgene expression in the immature myeloid compartment rather than in mature myeloid progeny in vivo 2006 ·Cytotherapy ·Eike C. Buss, Stephanie Laufs, Sonja Naundorf, Klaus Kuehlcke, (unknown), W. Jens Zeller, Stefan Früehauf	1
15	Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndrome 2004 ·European Journal Of Haematology ·Manfred Hensel, Eike C. Buss, Markus Tiemann, Reza Parwaresch, M. Libicher, Stefan Früehauf, Anthony D. Ho	4
16	Myeloablative Conditioning in Myelofibrosis using i.v. Treosulfan and Autologous Peripheral Blood Progenitor Cell Transplantation with High Doses of CD34+ Cells Results in Hematologic Responses - Follow-Up of Three Patients. 2004 ·Blood ·Stefan Früehauf, Eike C. Buss, Julian Topaly, Hans Kreipe, Anthony D. Ho	2
17	Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option? 2003 ·Drug Resistance Updates ·Stephanie Laufs, Eike C. Buss, W. Jens Zeller, Stefan Früehauf	3
18	The FBMD-1 stroma cell line secretes a unique moiety which can increase retroviral transduction of lineage-committed and primitive human peripheral blood progenitor cells 2001 ·Cancer Gene Therapy ·Eike C. Buss, Bernd Schiedlmeier, Anthony D. Ho, W. Jens Zeller, Stefan Früehauf	4
19	Soluble Bone Marrow Stroma Factors Improve the Efficiency of Retroviral Transfer of the Human Multidrug Resistance 1 Gene to Human Mobilized Peripheral Blood Progenitor Cells 1999 ·Human Gene Therapy ·Bernhard Schiedlmeier, Eike C. Buss, Marlon R. Veldwijk, W. Jens Zeller, Stefan Früehauf	8
20	Protection of Hematopoietic Stem Cells from Chemotherapy-Induced Toxicity by Multidrug-Resistance 1 Gene Transfer 1998 ·Recent results in cancer research ·Stefan Früehauf, (unknown), Eike C. Buss, Patrick Hundsdoerfer, Marlon R. Veldwijk, Rainer Haas, W. Jens Zeller	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact